Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119883 | 0.82 | KDM1A (0.79) | KDM1ARCOR1KEAP1 | |
| SCHEMBL31087460 | 0.80 | KDM1A (0.84) | KDM1ARCOR1KEAP1 | |
| Sulfuric Acid SCHEMBL29358305 | 0.79 | KDM1A (0.78) | KDM1ARCOR1KEAP1 | |
| Sulfuric Acid SCHEMBL28198732 | 0.77 | KDM1A (0.76) | KDM1ARCOR1KEAP1 | |
| SCHEMBL135811 | 0.77 | KDM1A (0.77) | KDM1ARCOR1KEAP1 | |
| SCHEMBL2476060 | 0.77 | KDM1A (0.77) | KDM1ARCOR1KEAP1 | |
| SCHEMBL15873843 | 0.77 | KDM1A (0.77) | KDM1ARCOR1KEAP1 | |
| SCHEMBL28176727 | 0.75 | KDM1A (0.66) | KDM1ARCOR1KEAP1 | |
| SCHEMBL28868015 | 0.74 | KDM1A (0.83) | KDM1ARCOR1KEAP1 | |
| SCHEMBL17888971 | 0.73 | KDM1A (0.56) | KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| EP-3230500-B1 | METHODS OF ORIENTING MULTIFILAMENT YARN AND MONOFILAMENTS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS THEREOF | TEPHA INC (US) | 2025-06-18 | — | — | EP | claimed |
| EP-3678715-B1 | CALENDERED SURGICAL MESHES COMPRISING POLYHYDROXYALKANOATES | TEPHA INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-3802062-B1 | METHODS FOR 3D PRINTING OF POLY-4-HYDROXYBUTYRATE | TEPHA INC (US) | 2024-09-18 | — | — | EP | claimed |
| WO-2024044654-A2 | PARENTERAL COMPOSITIONS OF ZILEUTON AND METHODS OF USE | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-02-29 | — | — | WO | claimed |
| EP-3174987-B1 | MRGPRX2/MRGPRB2 EXPRESSING CELL BASED ASSAY TO DETECT PSEUDO-ALLERGIC DRUG REACTIONS AND TO IDENTIFY BLOCKERS TO PREVENT THE ADVERSE REACTIONS | UNIV JOHNS HOPKINS (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3452122-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2023-03-22 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4630011-A2 | PREVENTION AND/OR TREATMENT OF COLONIC GROUP 3 INNATE LYMPHOID CELLS (ILC3)-MEDIATED DISEASES | Duke University (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025078209-A1 | ANTIBIOTIC COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-17 | — | — | WO | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-12161630-B2 | Methods to control infection using new generation small molecule growth inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | disclosed |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023012280-A1 | TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS | ZAMBON S.P.A. (IT) | 2023-02-09 | — | — | WO | disclosed |
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220325236-A1 | BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF | CELLUM BIOMEDICAL, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11345884-B2 | Biocompatible conditioned cell medium compositions and uses thereof | CELLUM BIOMEDICAL, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220119669-A1 | GLOVES WITH DURABLE LUBRICITY AND IMPROVED WET DONNING, AND METHODS THEREOF | HYDROGLYDE COATINGS LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | KDM1A 3423/4885RCOR1 3859/4885KEAP1 914/4885 |
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | SMURF1, SMURF2, SMYD3 | KDM1A 1837/4885RCOR1 2092/4885KEAP1 1728/4885 |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | CFTR, ELANE, IL5 | KDM1A 3299/4885RCOR1 4776/4885KEAP1 1673/4885 |
| US-12161630-B2 | Methods to control infection using new generation small molecule growth inhibitors | SMURF1, SMURF2, SMYD3 | KDM1A 1837/4885RCOR1 2092/4885KEAP1 1728/4885 |
| US-20250109110-A1 | BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | KDM1A 4446/4885RCOR1 3554/4885KEAP1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.